TABLE 2

Mean ± SD of rCMRglc (μmol/100 g/min) in Each Cerebral Cortex Under Isoflurane, Ketamine/Xylazine, and Awake

Region and anesthesia2-14C-DG autoradiography18F-FDG PET% diff.
Frontal cortex
 Isoflurane25.1 ± 7.524.1 ± 6.0−4.0
 Ketamine/xylazine40.3 ± 5.648.1 ± 4.1+19.5**
 Awake70.3 ± 9.664.5 ± 9.4−8.3*
Parietal cortex
 Isoflurane26.4 ± 10.326.3 ± 6.1−0.5
 Ketamine/xylazine42.3 ± 6.149.3 ± 7.2+16.6
 Awake74.0 ± 13.561.2 ± 6.6−17.3*
Temporal cortex
 Isoflurane29.7 ± 10.224.7 ± 6.0−16.8*
 Ketamine/xylazine42.7 ± 9.851.4 ± 4.0+20.4
 Awake53.0 ± 10.553.5 ± 8.2+0.9
Occipital cortex
 Isoflurane30.9 ± 11.728.9 ± 8.9−6.5
 Ketamine/xylazine42.1 ± 10.247.4 ± 8.4+12.5
 Awake73.0 ± 12.462.8 ± 11.7−13.9*

  • ↵* P < 0.05; comparison between individual 2-14C-DG and 18F-FDG values (paired t test).

  • ↵** P < 0.01; comparison between individual 2-14C-DG and 18F-FDG values (paired t test).

  • % diff. = percent difference between means of 2-14C-DG and 18F-FDG determinations.